Are Stem Cells FDA Approved? Understanding the Regulatory Landscape

“Are stem cells FDA approved?” It is one of the most common questions people ask when they start researching regenerative medicine, and the answer is more nuanced than most clinic websites want you to believe.

The short answer: one type is. The rest exist in a regulatory gray area that ranges from legitimate clinical research to outright fraud. Understanding this field is critical for protecting yourself, your health, and your wallet.

This guide breaks down exactly what the FDA has and has not approved, how the regulatory framework works, and how to evaluate whether a stem cell treatment being offered to you is legitimate.

The Only FDA-Approved Stem Cell Therapy

As of 2024, the only FDA-approved stem cell therapy is hematopoietic stem cell transplantation, what most people know as a bone marrow transplant. This procedure uses stem cells from bone marrow, peripheral blood, or umbilical cord blood to reconstitute the blood and immune system.

FDA-approved indications for hematopoietic stem cell transplant include:

• Blood cancers: Leukemia, lymphoma, multiple myeloma
• Bone marrow failure syndromes: Aplastic anemia, myelodysplastic syndromes
• Certain immune deficiency disorders: Severe combined immunodeficiency (SCID)
• Select inherited metabolic disorders: Such as Hurler syndrome

These transplants are performed in hospital settings by specialized hematologist-oncologists. They involve intensive conditioning regimens (chemotherapy and sometimes radiation) and carry significant risks including graft-versus-host disease, infection, and organ damage. They are serious medical procedures for serious medical conditions.

This is worlds apart from the stem cell injections offered at strip-mall clinics for knee pain, anti-aging, or autoimmune conditions.

Cord Blood Banking: FDA-Regulated but Limited

The FDA regulates cord blood products through a biologics licensing pathway. There are currently several FDA-approved cord blood products from public cord blood banks, but their approved use is exclusively for hematopoietic reconstitution, the same indications as bone marrow transplant.

Private cord blood banking, where families store their newborn’s cord blood for potential future personal use, is a different matter. These banks are FDA-registered and must follow current Good Tissue Practice (cGTP) standards, but the stored cord blood itself is not an FDA-approved product. The probability of a child needing their own stored cord blood is estimated at roughly 1 in 2,700 to 1 in 200,000, depending on the study cited.

Any clinic claiming to use “FDA-approved cord blood stem cells” for orthopedic, neurological, or cosmetic purposes is misrepresenting the regulatory status of these products.

21 CFR Part 1271: The Regulatory Framework

The FDA regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. This regulation establishes a tiered system that determines how much oversight a product requires:

The “Same Surgical Procedure” Exception (Section 1271.15)

A tissue product is exempt from FDA premarket approval if it meets ALL of the following criteria under Section 361 of the Public Health Service Act:

1. Minimal manipulation: The tissue is not processed beyond what is needed to preserve it
2. Homologous use: The tissue performs the same function in the recipient as in the donor
3. Not combined with another article (except water, saline, or sterilizing agents)
4. Either: For autologous use (from the patient themselves), for a first- or second-degree relative, or for reproductive use

This is the exception that many stem cell clinics attempt to operate under. The argument typically goes: “We are taking your own fat tissue, processing it minimally, and re-injecting it, therefore we do not need FDA approval.”

The FDA has pushed back hard on this interpretation, particularly regarding what constitutes “minimal manipulation” of adipose (fat) tissue. In November 2017, the FDA issued final guidance clarifying that enzymatic digestion of fat tissue to isolate the stromal vascular fraction (SVF) constitutes more than minimal manipulation, making these products subject to FDA regulation as biological drugs.

What This Means in Practice

FDA Enforcement Actions: Warning Letters and Beyond

The FDA has not simply issued guidance and walked away. The agency has taken concrete enforcement actions against stem cell clinics operating outside regulatory boundaries:

• US Stem Cell Inc. (2018): The FDA obtained a permanent injunction against this Florida clinic after patients were blinded by unapproved stem cell injections into the eye for macular degeneration. This case was a watershed moment in FDA enforcement.
• Cell Surgical Network (2021): The FDA pursued legal action against this network of clinics offering adipose-derived SVF treatments, resulting in a federal court ruling that their products were unapproved biological drugs.
• Liveyon (2019): This cord blood product distributor was linked to serious adverse events including sepsis from contaminated products. The FDA issued a warning and the company recalled products.

Despite these actions, enforcement has been inconsistent. Hundreds of clinics continue to offer unapproved stem cell treatments across the United States. A 2016 study in Cell Stem Cell identified over 570 clinics marketing stem cell treatments at nearly 700 locations nationwide.

How to Evaluate if a Stem Cell Treatment Is Legitimate

If you are considering a stem cell treatment, here is a framework for evaluating its legitimacy:

1. Ask About the Regulatory Pathway

A legitimate provider should be able to clearly explain whether their treatment is: (a) FDA-approved, (b) part of an FDA-authorized clinical trial with an Investigational New Drug (IND) application, or (c) operating under the same-surgical-procedure exception with a clear rationale. If they cannot answer this question clearly, that is a red flag.

2. Check ClinicalTrials.gov

If a clinic claims to be conducting research, verify that their study is registered at ClinicalTrials.gov. Legitimate clinical trials have IRB oversight, informed consent procedures, and data safety monitoring boards.

3. Understand What You Are Actually Getting

Many products marketed as “stem cell therapy” contain few or no viable stem cells. Amniotic and umbilical cord tissue products, for example, have been independently tested and found to contain zero viable stem cells in multiple analyses. Ask for documentation of the cell count, viability, and characterization of what is being injected.

4. Look for Published Evidence

Peer-reviewed publications in indexed medical journals carry more weight than website testimonials or conference presentations. Look for evidence specific to the condition being treated, the cell type being used, and the route of administration.

5. Get a Second Opinion

Consult with an academic physician at a university medical center. They can provide an independent assessment of whether a proposed stem cell treatment is scientifically sound and appropriately regulated.

What About Treatments Offered Outside the United States?

Medical tourism for stem cell treatments, particularly to Mexico, Panama, Colombia, and various Asian countries, has exploded in recent years. Some of these international clinics are affiliated with legitimate researchers and use culture-expanded mesenchymal stem cells that would require an IND in the United States.

However, the regulatory standards, quality controls, and legal protections vary enormously by country. Some considerations:

• Cell manufacturing standards may not be equivalent to FDA cGMP requirements
• Adverse event reporting may be minimal or nonexistent
• Legal recourse in the event of injury may be limited
• Follow-up care must be coordinated across borders
• Some international clinics are excellent; many are not, due diligence is essential

Frequently Asked Questions

Are stem cell injections for knee arthritis FDA approved?

No. No stem cell injection for knee osteoarthritis has been approved by the FDA. Bone marrow aspirate concentrate (BMAC) injections for joints are widely performed under the same-surgical-procedure exception and are generally tolerated by the FDA, but they are not “FDA approved.” Adipose-derived stem cell injections for joints have been the subject of FDA enforcement actions. Any clinic claiming FDA approval for stem cell knee injections is misrepresenting the facts.

Will stem cell therapy ever be FDA approved for more conditions?

Almost certainly, yes, but the timeline is measured in years, not months. Multiple stem cell products are in Phase II and Phase III clinical trials for conditions including heart failure, Crohn disease, graft-versus-host disease, and spinal cord injury. The path from clinical trial to FDA approval typically takes 5 to 15 years and requires demonstrating both safety and efficacy through rigorous, controlled studies.

Is it illegal to get stem cell treatment in the US?

It is not illegal for a patient to receive stem cell treatment. However, it may be illegal for a provider to manufacture and administer an unapproved biological product without an IND from the FDA. The enforcement risk falls on the clinic, not the patient. That said, patients bear the health risk of receiving an unregulated product, and they may have limited legal recourse if something goes wrong.

What is the difference between FDA “approved” and FDA “cleared”?

“FDA approved” applies to drugs and biologics that have gone through the full premarket approval process, including clinical trials demonstrating safety and efficacy. “FDA cleared” typically applies to medical devices that have been shown to be substantially equivalent to a previously marketed device through the 510(k) pathway. Some stem cell clinics use “FDA cleared” to describe their equipment (centrifuges, processing kits) while implying that the treatment itself has FDA endorsement, this is misleading.

Related Reading

This article is part of our complete guide to stem cell therapy. For a full overview of stem cell types, applications, evidence, and what to expect, see our pillar article: Stem Cell Therapy: The Complete Guide.